The formation and integration of neural networks is dependent on the actions of the master control neurotransmitter serotonin (5-HT) acting through multiple 5-HT receptor subtypes. During brain development 5-HT regulates morphogenetic activities, such as neural differentiation, axon outgrowth, and configuration of synaptic connections. In the adult brain, midbrain raphe serotonergic neurons project to a variety of brain regions and modulate a wide range of physiological functions. Several lines of evidence indicate that genetically determined variability in serotonergic gene expression influences complex behaviour and may lead to conditions with increased anxiety, depression, and aggression. Investigation of the regulation of serotonergic gene transcription and its impact on neural development and plasticity will spur general interest to identify serotonergic gene-related molecular factors underlying disease states and to develop more effective treatment strategies. Gene targeting strategies have increasingly been integrated into investigations of brain function and along with the fading dogma of a limited capacity of neurons for regeneration, reproducibility, and plasticity, it is realized that gene transfer techniques using efficient viral vectors in conjunction with neuron-selective transcriptional control systems may also be applicable to complex disorders of the brain. Given the fact that the 5-HT system continues to be an important target for large-scale drug development and production, novel strategies aiming toward the modification of 5-HT function at the level of gene expression are likely to be exploited by enterprises participating actively in the introduction of alternative therapeutic approaches.
Introduction
Elucidation of the molecular mechanisms underlying neuronal communication, particularly with respect to defining the transfer of receptor-detected signals across cell membranes to intracellular effectors and the central role of neurotransmitter uptake in the termination of this signalling has been among the most remarkable advances in neuroscience. The multiplicity and plasticity of neurotransmitter receptors, their heterogeneous brain distribution including pre-and postsynaptic localization, their differential regulation and cross-talk, and their role in the pathophysiology and treatment of various psychiatric disorders has increasingly attracted research efforts. Considerable progress has resulted from the functional and molecular characterization of genes relevant to neurotransmitter systems ; from pharmacological studies relating the actions of psychoactive drugs to discrete effects at different receptor-effector systems, and from the molecular dissection of long-term modulatory changes as a consequence of altered gene expression.
The actions of neurotransmitters on neural function are therefore increasingly related to their regulation of complex intracellular signal transduction events. These signalling pathways mediate most actions of transmitters and modulators, including fast alterations in cell firing, short-term modulation in neuronal metabolism and receptor sensitivity, and long-term adaptation of gene expression. Inadequate adaptive responses to environmental stressors as a consequence of genetic and\or developmental vulnerability are likely to contribute to the aetiopathogenesis of psychiatric disorders, such as depression or bipolar disorder. At the molecular level psychiatric disorders may result from aberrant regulation of neuron-specific gene expression and may eventually be characterized by disruption of intra-and interneuronal signalling through inappropriate activation or inactivation of regulatory proteins, including nuclear transcription factors. Increasing knowledge of the molecular aetiology of mental illness, coupled with the identification of key cellular pathways involved, is now paving the way for rational drug design, targeting individual genes or their products.
While early steps of development of the brain are dominated by genetically determined local chemical signals between developing cells, it is now clear that at later stages of development (the so-called period of ' finetuning ' of synaptic connections) and even during adult life, particularly connectivity of the cerebral cortex is influenced by sensory inputs from the environment. Among the prime candidate signals for the fine-tuning of cortical connections is serotonin (5-HT) acting at more than 14 receptor subtypes (Lauder, 1993) . Since transient serotonergic projections to the primary sensory cortices are detectable in early stages of development, serotonergic terminals are likely to play an important role in integration of cortical connectivity (Azmitia and Whitaker-Azmitia, 1997 ; Cases et al., 1996) .
Given the fact that the 5-HT system continues to be an important target for drug development, novel therapeutic strategies aiming towards the modification of 5-HT function at the level of gene transcription are likely to be exploited by the pharmaceutical industry. This overview describes pertinent aspects of serotonergic gene expression and its relevance for central 5-HT system plasticity. Based on the growing body of evidence that expression variability of proteins that regulate the central 5-HT system is associated with complex behavioural traits, it specifically emphasizes transcriptional control regions of serotonergic genes as potential targets for antidepressant drug development.
Serotonin receptors

Serotonin receptor-dependent signal transduction pathways
Pharmacological classification based on ligand-binding experiments and on the study of functional responses to agonists\antagonists were initially utilized to define four 5-HT receptor subfamilies, 5-HT " -% . Molecular biology has subsequently both confirmed this classification and also revealed the existence of novel 5-HT receptor subtypes for which little pharmacological or functional data exists (5-HT "E , 5-HT "F , 5-HT &A , 5-HT &B , 5-HT ' , and 5-HT ( ) (Hoyer and Martin, 1997) . As an indicator that this is still work in progress, an additional subunit B of the 5-HT $ receptor has recently been discovered (Davies et al., 1999) . The present challenge is to determine the physiological relevance of these gene products, establish their function as endogenous receptors, find selective ligands, and determine potential therapeutic applications of these compounds.
Current research is also focusing on participating constituents and regulatory mechanisms of gene transcription, mRNA processing and translation, as well as intracellular trafficking and post-translational modification of proteins relevant to synaptic and post-receptor signalling. Crucial information is derived from the analysis of transcriptional control systems of 5-HT receptor genes as well as from modelling complex behaviour and novel therapeutic strategies in transgenic animals. The new insights into neural plasticity and complexity of gene regulation in 5-HT subsystems will eventually provide the means for novel approaches of studying serotonergic drug-induced long-term adaptational processes at the molecular level.
Signalling through 5-HT receptors involves different transduction pathways, and each receptor subtype generally modulates second-messenger systems and multiple effectors (Figure 1 ). While the 5-HT $ receptor is a ligandgated ion channel, all other 5-HT receptor subtypes are coupled to signal-transducing heterotrimeric G proteins. The G-protein cycle, at the centre of receptor-effector communication, serves the critical roles of first amplifying extracellularly generated receptor-mediated signals and then transmitting these integrated signals to effectors. This is the basis for complex intracellular signal-processing networks which allow the cell to respond both rapidly and to low-stimulus concentrations. G proteins are heterotrimeric guanine nucleotide-binding proteins which convey information from cell surface receptors to various effectors including adenylyl cyclase (AC), phospholipase C (PLC), and ion channels (Taylor, 1990) . The G proteins are derived from a large gene family, and the α-subunits define several major classes with more than 20 isotypes (Simon et al., 1991) . Furthermore, G-protein signalling is modulated by various regulator proteins (RGS) which are expressed in the brain in a region-specific fashion (Gold et al., 1997) . 5-HT % , 5-HT ' , and 5-HT ( stimulate AC mainly through a stimulatory G protein (G s ), leading to increased cAMP-dependent protein kinase A (PKA) activity. The 5-HT " subtypes (1A, 1B, 1D, 1E) inhibit AC with a rapid decrease of cAMP concentrations via inhibitory G proteins (G i ). cAMP modulates the expression of genes containing a cAMP response element (CRE) in their 5h-flanking regulatory regions. 5-HT #A -C receptors stimulate PLC through Gq protein isotypes with subsequent activation of protein kinase C (PKC). Finally, K + and Ca# + channels are modulated via G proteins.
Regulation of gene expression by serotonin receptors
5-HT modulates pre-and postsynaptic gene expression in Figure 1 . Serotonin (5-HT) receptor-mediated intracellular signalling and modulation of gene expression. Induction of secondary messenger pathways leads to the activation of primary response genes (immediate early genes, IEGs). Many of these are nuclear transcription factors (TFs) that are activated in a stimulus-and tissue-specific way. Following their activation they bind to specific DNA motifs in the promoter\regulatory regions of a variety of late-response genes (LRGs). Depending on cell type and the presence of other factors, co-factors, and activators, IEGs can act either as inducers or repressors of LRG expression. The differential expression of the LRGs is responsible for the different phenotypes displayed by the various cells making up a multicellular organism. G s \G i \G q , heterotrimeric G proteins ; DAG, diacylglycerol ; IP % , inositol 1,3,4,5-tetrakisphosphate ; nP % R, nuclear IP % receptor ; CaCMK II, calcium\calmodulin-dependent kinase II ; SRE, serum response element ; SRF, serum response factor ; CaRE, calcium response element ; CRE, cAMP response element ; CREB, CRE binding protein ; AP1, activating protein 1 and AP1 response element ; TATA, TATA box and transcription start site ; P, Phosphorylation. the brain. 5-HT #A -C receptors induce, via PLC-activated second messengers (inositol polyphosphates, diacylglycerol, and Ca# + ) mitogenesis in non-neuronal cells and are involved in the neural plasticity of post-mitotic neurons (Julius, 1991) . The pattern of gene expression is different from chronic vs. acute stimulation of 5-HT receptor subtypes. Signalling to the nucleus through 5-HT receptors involves different second-messenger systems, and each receptor subtype regulates multiple effectors (Figure 1 ). Long-term adaptive changes in neuronal function following administration of serotonergic drugs such as tricyclics or selective 5-HT uptake inhibitors (SSRIs) is one such example of molecular plasticity triggered by 5-HT receptors. The role of 5-HT receptors in the control of transcriptional events and immediate early gene (IEG) regulation is highly complex.
Specific changes in postsynaptic signal transduction pathways following neurotransmitter and drug-induced receptor activation, such as increases in cAMP, diacylglycerol (DAG), and inositol triphosphate (IP $ ) concentrations or modulation of cytoplasmic and nuclear Ca# + levels eventually trigger rapid induction of IEG expression. cAMP acts by stimulating PKA to phosphorylate a group of nuclear transcription factors (TFs) including the cAMP response element-binding protein (CREB). While DAG-modulated PKC activity changes the phosphorylation state of a variety of transcription factors, regulation of Ca# + -inducible genes involves Ca# + \ calmodulin-dependent kinase II, which also phosphorylates CREB and other TFs such as the serum response factor (SRF). These proteins, referred to as third messengers, induce the expression of several IEGs such as fos, jun, and zif268. IEGs themselves encode TFs, including the ATF\CRE\AP1 superfamily of BZip proteins, which regulate the expression of a large variety of other genes (late-response genes). While the transcriptional induction of IEGs occurs within minutes of stimulation and is very transient, their gene regulatory properties lead to adaptational effects over long time periods of days and months. The IEGs therefore provide a link between receptor\signal transduction pathways and the process of gene expression, which provides the basis for long-term neuronal adaptation. Although few data are available to date, it is highly likely that IEG expression is responsive to 5-HT receptor activation in the brain (Bhat et al., 1992 ; Lucas et al., 1997 ; Morinobu et al., 1997) .
Transcriptional control of serotonin receptor genes
The molecular characterization of different 5-HT receptor gene families has facilitated the elucidation of the mechanisms involved in the expression, regulation, and internalization of those receptors. Previously, studies have concentrated primarily on post-transcriptional processing of receptor mRNA and post-translational modification of the receptor protein. Gerald et al., 1995 ; Heidmann et al., 1997 ; Olsen et al., 1999) are alternatively spliced, thus increasing the complexity of the 5-HT receptor families. A splice variant of the 5-HT #C receptor appears to be a nonfunctional transcript (Canton et al., 1996) , while RNA editing of this subtype in the second intracellular loop confers differential receptor functionality.
Although many features of 5-HT receptor subtypes, subunits, and their spliced or edited isotypes have been disclosed, little information is available on the genetic elements and TFs involved in the regulation of their gene expression ( Figure 2 ). The basal promoter and associated regulatory elements are located upstream of a transcribed gene. In contrast to constitutive promoters (e.g. viral long terminal repeats, LTR, or immediate early promoter of the cytomegaly virus, CMV-IE) which effectively drive expression in a large variety of tissues, tissue-selective regulatory elements confer cell-restricted actitvity such that the gene is transcribed only in distinct neurons or glial cells. Consequently, cis-acting elements (the 5h-flanking regulatory portion of a gene) and trans-acting factors (DNA-binding proteins involved in transcriptional control) which may be important in the regulation and cell or tissue-selective expression of 5-HT receptor genes are being identified and characterized at an increasing rate.
Transcriptional control regions have been cloned for several 5-HT receptor subtypes and functional promoter mapping data are available for the 5-HT "A (Albert et al., 1996 ; Parks and Shenk, 1996 ; Storring et al., 1999) , 5-HT #A (Ding et al., 1993 ; Du et al., 1994 Du et al., , 1995 Garlow et al., 1994 ; Shih et al., 1996 ; Toth and Shenk, 1994) , 5-HT #C (Bloem et al., 1993 ; Xie et al., 1996) , and 5-HT $ receptor genes (Bedford et al., 1998) in different mammalian species. The findings provide evidence that significant differences exist among these promoter regions, suggesting that regulation of 5-HT receptor genes may involve distinct control mechanisms (Figure 2 ). Potential bindings sites for a variety of TFs, such as Sp1, AP1, AP2, and CRE, as well as sequences comprising selective activators and repressors, arrayed upstream of the core promoters were reported to modulate gene transcription.
For example, complex transcriptional control mechanisms have been shown to be responsible for the cellselective and antidepressant-induced regulation of the 5-HT #A receptor (Toth, 1996 ; Toth and Shenk, 1994) . Repressor domains in the gene's 5h-flanking region are the principal determinants to generate neuronal cell-specific transcription. Glial cell expression is achieved through cell-selective promoter activation. Down-regulation of the 5-HT #A receptor by antagonists, such as the atypical antidepressant mianserin, is mediated by a drug response sequence in the transcriptional apparatus of the receptor gene.
Work from several groups demonstrated that 5-HT receptor gene expression is modulated by glucocorticoids (Chaouloff, 1995) . Adrenalectomy increases 5-HT "A receptor mRNA and protein, whereas dexamethasone attenuates the expression of the 5-HT "A receptor gene (Chalmers et al., 1994 ; Zhong and Ciaranello, 1995) . Glucocorticoid-mediated transcriptional regulation was also reported for other subtypes, including 5-HT "B (Mendelson and McEwen, 1992) , 5-HT ' , and 5-HT ( (Le Corre et al., 1997 ; Yau et al., 1997) . Advanced analyses of transcriptional control regions of 5-HT receptor genes and their interactions with tissue-selective trans-acting factors will not only determine the molecular mechanisms underlying regulation and expression of 5-HT receptor genes during neurodevelopment, but is also likely to establish phenomena such as up-and down-regulation of receptor proteins following chronic pharmacological manipulation as consequences of genomic events.
Tryptophan hydroxylase
The first step of 5-HT biosynthesis in serotonergic neurons is catalysed by the rate-limiting enzyme tryptophan hydroxylase (TPH). Abnormalities in TPH activity have been implicated in a wide range of psychiatric disorders (Abbar et al., 1995) . The human gene on chromosome 11p is a member of the aromatic amino acid hydroxylase family, spans a region of 29 kb, and contains at least 11 exons (Boularand et al., 1995) . An unusual splicing complexity in the 5h-untranslated region (5h-UTR) results in at least four TPH mRNA species transcribed from a single transcriptional start site. Although a detailed analysis of the gene's transcriptional control region is still lacking, DNA elements important for serotonergic neuron-specific expression of TPH appear to be contained in 6.1 kb of 5h-flanking transcriptional control region of the mouse TPH gene. Moderate levels of β-galactosidase expression in transgenic mice carrying the TPH promoter\lacZ fusion gene were detected in serotonergic neurons of the midbrain raphe complex, whereas a shorter 5h-flanking sequence of 1.1 kb directed no detectable serotonergic tissue-specific reporter gene expression (Huh et al., 1994) . Immortalized pinealocytederived cell lines could be established by fusion of the 6.1-kb 5h-flanking region to the SV40 T-antigen and application of this construct to mice (Son et al., 1996) .
Monoamine oxidase A
Monoamine oxidase A (MAOA) oxidizes 5-HT, norepinephrine as well as dopamine, and is expressed in a cell type-specific manner. The human MAOA gene is localized on chromosome Xp11.23, extends over 70 kb, and is composed of 15 exons (Shih et al., 1993 ; Zhu et al., 1992) . Two species of MAOA mRNA, 2.1 and 5.0 kb, are generated by the use of two alternative polyadenylation sites. While there is considerable controversy regarding the site where mRNA synthesis is initiated, tissue-specific length variability of the 5h-UTR with multiple transcription start sites clustered primarily around a initiator element which may also act as a negative cis element have been reported (Denney et al., 1994 ; Zhu et al., 1994) . The core promoter region contains two 90 bp repeat sequences, which are further divided into four imperfect tandem repeats, each containing an Sp1 binding site in reversed orientation (Zhu and Shih, 1997) .
Abnormalities in MAOA activity have been implicated in a wide range of behavioural traits and psychiatric disorders. Deficiency in MAOA due to a hemizygous chain termination mutation of the MAOA gene has recently been shown to be associated with mild mental retardation and occasional episodes of impulsive aggression and hypersexual behaviour in affected males from a single large family (Brunner et al., 1993) . Interestingly, male mice lacking the MAOA gene also exhibit aggressive behaviour and increased reactivity to stress. However, screening of volunteers in the general population and from putative high-risk groups for possible MAO deficiency states suggests that marked MAO deficiency states are very rare (Schuback et al., 1999) .
A functional 30-bp repeat polymorphism was recently identified in the promoter region of the MAOA gene that differentially modulates gene transcription (Deckert et al., 1999 ; Sabol et al., 1998) . Variation in the number of repeats (3-5) of this MAOA gene-linked polymorphic region (MAOA-LPR) had different transcriptional efficiency when fused to a luciferase reporter gene and transfected into cell lines. The transcriptional efficiency of the 3-repeat allele was 2-fold lower than those with longer repeats. Preliminary evidence indicates that length variation of the MAOA-LPR confers vulnerability to dissocial behaviour in alcohol-dependent males (Samochowiec et al., 1999) and may be a risk factor for panic disorder in female patients (Deckert et al., 1999) .
Serotonin transporter
The transporter as modulator of 5-HT homeostasis
While 5-HT acts as a master control neurotransmitter within a highly complex system of neural communication mediated by multiple pre-and postsynaptic 5-HT receptor subtypes, high-affinity 5-HT transport into the presynaptic neuron is mediated by a single protein complex. The 5-HT transporter removes 5-HT from the synaptic cleft and determines the magnitude and duration of postsynaptic receptor-mediated signalling, thus playing a pivotal role in the fine-tuning of 5-HT neurotransmission (for review see Blakely et al., 1994 ; Lesch, 1997) . The 5-HT transporter is also the initial target for several antidepressant drugs (e.g. clomipramine, fluoxetine), anorectic drugs (-fenfluramine, ' Redux '), and drugs of abuse (substituted amphetamines such as MDMA, ' Ecstasy '), some of which are potent neurotoxins. There have been remarkable advances in the elucidation of the 5-HT transporter gene's organization and regulation. A polymorphism in the 5h-flanking transcriptional control region of the 5-HT transporter gene that results in allelic variation in functional 5-HT transporter expression is associated with anxiety-and depression-related personality traits . Preliminary studies suggest that it may also influence the risk to develop affective spectrum disorders (Furlong et al., 1998) and the response to selective 5-HT reuptake inhibitors (Smeraldi et al., 1998) .
Progress in 5-HT transporter gene inactivation (knockout) studies are also changing views of the relevance of adaptive 5-HT uptake function and 5-HT homeostasis in brain development and plasticity as well as processes underlying drug dependence and neurodegeneration Sora et al., 1998) . Despite a growing body of evidence for a potential role of the 5-HT transporter in the integration of synaptic connections in the mammalian brain during development, adult life, and old age, detailed knowledge of the molecular mechanisms involved in this fine-tuning process is only just beginning to emerge.
Regulation of 5-HT transporter gene expression
The human and murine 5-HT transporter genes (SLC6A4) are located on chromosome 17q12.2 and chromosome 11, respectively. Both are composed of 14 exons spanning approx. 35 kb and with conservation of the exon\intron organization and, to a lesser extent, the 5h-flanking noncoding as well as regulatory sequences Lesch et al., 1994) (Figure 3 ). The role of these transcription factor motifs in the regulation of human and murine 5-HT transporter gene transcription was studied by transfection studies using reporter gene fusion constructs of 5h-flanking sequences (Heils et al., 1995 . Functional mapping revealed that the expression of the 5-HT transporter gene is regulated by a combination of positive and negative cis-acting elements operating through a basal promoter unit defined by a TATA-like motif and that the information contained within 2.2 kb of a 5h-flanking sequence is sufficient to confer its cell-specific expression.
Transcriptional activity of the human 5-HT transporter (5-HTT) gene is modulated by a polymorphic repetitive element (5-HTTLPR) located upstream of the transcription start site. While the 5-HTTLPR is unique to humans and simian primates, the majority of alleles are composed of either 14 or 16 repeat elements in humans, while alleles with 18 or 20 repeat elements are rare . In the 5-HTTLPR of rhesus monkeys (rh5-HTTLPR) an alternative locus for length variation (polymorphic locus 2) generated by a 21 bp insertion\ deletion is associated with CSF 5-HIAA concentrations and aggressive behaviour. The 5-HTTLPR variants display unique G string-dependent DNA secondary structures that have the potential to regulate the transcriptional activity of the associated 5-HT transporter gene promoter. The secondary structure of the 5-HTTLPR is also likely to precipitate a 381-bp somatic deletion in the 5-HT transporter gene's promoter region [del(17)(q12)] observed in 20-40 % of genomic DNA isolated from human brain and mononuclear blood cells (Figure 3 ). The localization of the deletion breakpoints adjacent to identical putative signal sequences (CAGCC) suggests a recombinase-like rearrangement event. Thus, mosaicism of the 5-HT transporter gene promoterassociated del(17)(q12) may be regulated by tissue-specific as well as 5-HTTLPR genotype-dependent mechanisms.
The 5-HTTLPR confers allele-dependent differential transcriptional activity on the 5-HT transporter gene promoter when fused to a luciferase reporter gene and transfected into human 5-HT transporter expressing cell lines . In a recent study of 5-HTTLPR genotype effects on 5-HT transporter expression in human post-mortem brain, mRNA concentrations were significantly lower in the brainstem raphe complex of individuals with the low-activity variant (Little et al., 1998) . A similar genotype effect on 5-HT transporter availability was also found in a ["#$I]β-CIT SPECT study in healthy subjects (Heinz et al., In Press) . Furthermore, interactions between 5-HTLPR genotype and both platelet 5-HT uptake and content which is influenced by seasonal variation have also been observed Hanna et al., 1998) .
5-HT transporter gene transcriptional control region and gene transfer technologies
The characterization of the 5-HT transporter gene's 5h-flanking sequence identified a regulatory unit specific for serotonergic neurons in the midbrain raphe. The fusion of this 5-HT transporter gene regulatory unit to similar or unrelated genes may aid their expression in this specific neural subsystem and open the way to novel therapeutic strategies. Gene transfer strategies have increasingly been integrated into investigations of brain function with focus on cellular and molecular mechanisms of neuronal development, plasticity, and degeneration. These techniques are also under study as prospective treatment strategies for CNS disorders. One of the apparent uses for 5-HT transporter gene promoter and associated regulatory elements is to confer cell selectivity such that a transferred gene is transcribed only in serotonergic raphe neurons. The transcriptional control region of the 5-HT transporter gene has been studied for cell-selective gene expression, and their neuron-restricted activity has recently been documented by transfection into cultured cells (Heils et al., 1995 .
Efficient and safe strategies of targeting therapeutic genes to neurons or glial cells is the gold standard for CNS gene transfer to attain clinical relevance (Blo$ mer et al., 1996 ; Karpati et al., 1996 ; Tuszynski and Gage, 1996) . Although basically two alternative approaches for gene transfer procedures have been developed, the ex vivo (the transgene is introduced into a cell by a viral vector in vitro which is then grafted into the organism) and the in vivo strategy (the transgene is delivered into the organisms for in situ transduction of the cell), direct viral vectormediated gene transfer into target cells of the CNS is the favoured method (Lesch, 1999) . Viral vectors are replication-deficient viruses that contain the gene of interest flanked by a viral or cell-selective promoter and genes coding for packaging (Kaplitt and Makimura, 1997 ; Verhaagen et al., 1996) . While gene transfer with adenovirus and herpes simplex virus-derived constructs is transient, leading to a loss of the transgene during cell proliferation, retroviral and adeno-associated viral vectors are integrated into the host cell genome. Efficiency of transgene expression is related to the promoter driving the transgene and host immune response. Restricting the expression of immunogenic viral proteins synthesized in the transduced cell may ensure long-term activity of the transgene. Thus, replication-deficient lentivirus-based vectors, such as the human immunodeficiency virus type 1 (HIV-1), also provide powerful tools for gene delivery to brain neurotransmitter systems.
However, one of the major remaining challenges is targeted tissue-, or even better, cell-selective transgene expression in distinct neuronal or glial cell populations, an important requirement for therapeutic gene transfer techniques to the brain (Amado and Chen, 1999) . By incorporation of heterologous glycoproteins like the vesicular stomatitis virus-glycoprotein-G (VSV-G), pseudotyped lentiviruses have been designed to transduce a wide variety of different host cells, thus allowing an extension of the host range beyond cells expressing CD4. In order to achieve cell-selective transgene expression, techniques range from a specific site of vector delivery to the recent efforts of targeted provirus integration into the host's genome by expression trapping.
We have recently reported that primary cultures of serotonergic neurons are efficiently transduced by pseudotyped human HIV-1-derived vectors, generated by a three-plasmid expression system, and in which a lacZ transgene is driven by the murine 5-HT transporter gene promoter (m5-HTTP) (Figure 4 ). Brain region and 5-HT system specificity of transgene expression was confirmed by stereotactic application of vector into the midbrain raphe complex of CD1 mice and of mice with a targeted inactivation of the 5-HT transporter gene (Heils et al., unpublished observations) . Stable β-galactosidase expression was observed over a period of 12 wk in these mice. These results show that lentivirus-based vectors, such as HIV-1, can efficiently transduce embryonic as well as non-dividing cells with a gene of interest, and that a serotonergic neuron-selective and region-specific transgene expression pattern can be achieved with the m5-HTTP independent from the site of virus integration. While Huh et al. (1994) demonstrated that a minimum of 6.1 kb of the 5h regulatory region of the murine TPH gene was required to ensure cell-selective promoter activity in serotonergic cells, the use of the significantly shorter m5-HTTP allows more space for inserting a transgene of interest into the vector and may therefore be more practical in gene transfer experiments. Given the important role of the central 5-HT system in complex physiological functions and its implication in several neuropsychiatric disorders, m5-HTTP-driven transgene expression may facilitate targeted modulation of this extensive neurotransmitter system.
Developing drugs that target serotonergic gene transcription
Given the fact that the 5-HT system continues to be an important target for large-scale drug production and development, novel therapeutic strategies targeting serotonergic gene transcription need to be explored. Traditionally, discovery of therapeutic agents has relied on random screening of large numbers of compounds for products that interfere with biological events associated with disease. Increasing knowledge of the molecular aetiology of human disorders, coupled with identification of the key proteins and cellular pathways involved, is now paving the way for rational drug design, targeting individual genes or their products.
Transcriptional control regions and their associated cis and trans regulatory elements are potential targets for modulation of transgene expression. A variety of physiological factors regulate gene expression, and some of these could be applied to modulate the activity of promoters in gene transfer strategies. As discussed in previous sections, gene regulation involves a large variety of TFs which activate or repress the transcription of specific genes, resulting in changes of the cellular phenotype. Many TFs have been identified and characterized, making disease-and\or tissue-specific targeting more feasible. TFs bind to specific motifs in the regulatory sequence of a target gene resulting in spatio-temporal alterations in promoter-driven gene transcription. Different stimuli lead to the activation or repression of different TFs. TFs have the potential to be highly specific in their target recognition, and TFs from different families may interact with each other when bound to DNA at . Gene transfer to neurons by a lentiviral vector. Vector constructs, in which all viral coding sequences have been deleted, accommodate a large transgene including a regulatory region (e.g. murine 5-HT transporter gene promoter, m5-HTTP), induce tissue-selective transcriptional regulation and high levels of stable expression, and retain significantly decreased acute and chronic toxicity. Vectors based on lentiviruses, such as HIV-1, are able to infect non-dividing neuronal cells (e.g. serotonergic neurons). After infection the vector RNA containing the gene of interest (reporter gene or therapeutic gene) is transcribed into DNA. The DNA forms a pre-integration complex with the accessory protein Vpr, the enzyme integrase, and the protein matrix. The localization sequences of these proteins enable the pre-integration complex to cross the nucelar membrane and the insertion of the DNA into the host genome by integrase. Gag, pol, vif, vpr, vpu, rev, tat , and nef are lentiviral genes. VSV-G, vesicular stomatitis virus-glycoprotein-G envelope. LTR, long terminal repeat. LTRs are unique cis-acting sequences that flank the virus genome and are essential for its life-cycle (adapted from Amado and Chen, 1999). composite response elements. This has two striking consequences : ubiquitous factors can affect cell specificity ; and closely related factors from a given family can produce very different regulatory patterns. Therefore, TFs play a key role in the control of development and differentiation, and thus make tempting targets for therapeutic intervention (Duman, 1998) . Several lines of evidence indicate that TFs are targeted by psychoactive drugs such as 5-HT #A/C receptor agonists and antagonists. The mechanisms by which they exert therapeutic effects still require to be studied in detail, but TFs such as fos and zif268 are believed to mediate between receptor-activated second-messenger systems and the transcriptional apparatus of genes involved in the complex functions of neuronal cells.
Indirect regulation of gene expression by steroid hormones, thyroid hormone, retinoic acid, and vitamin D $ , all of which bind to receptors of the same gene family (Reichel and Jacob, 1993) , appear to be a feasible strategy that may be employed to modulate expression of genes. The molecular definition of a hormonal response element allows a choice of sequence elements which can serve to regulate heterologous promoters. These elements would then be subject to modulation by natural or easily administered synthetic pharmacoactive molecules (Corti et al., 1996) . While it has previously been reported that glucocorticoids modulate 5-HT uptake and inhibitor binding, studies with 5-HTTLPR-containing sequences indicate a pronounced allelic variability in glucocorticoidinduced derepression of 5-HT transporter promoter activity (A. Heils et al., unpublished observations) . Another possibility of influence is the regulation by ions. It has been shown, principally from studies on G-string tetrastrand DNA structure (G4-DNA), that ions such as Na + and K + facilitate, while lithium inhibits the formation G4-DNA and thus have the potential to regulate the transcriptional activity of linked promoters (Lesch, 1997 ; Sen and Gilbert, 1990) . The use of ions is therefore a feasible way of achieving promoter-based regulation of genes in cells where promoter-associated G4-DNA elements are found. Since an increasing body of evidence suggests that hormones, ions, and therapeutic drugs directly interfere with serotonergic gene promoter activity, a future avenue of research will therefore be the investigation of indirect and direct effects of drugs known for their impact on the 5-HT system, and of experimental agents on the transcriptional apparatus of the 5-HT transporter gene, using in vitro systems and transgenic animals.
Conclusion and future directions
Novel strategies aiming towards the modification of serotonergic function at the level of gene transcription are likely to be derived from future studies. Identification of experimental drugs within the framework of these studies could set the stage for a rational approach to the design of drugs that act in a tissue-or disease-specific manner, target defined genes and proteins, and combine increased efficacy with reduced side-effects. Future benefits will stem from the potential development of techniques involving molecular cell biology, transgenics, and gene transfer technology that could facilitate drug design. Apart from the remarkable progress in the dissection of complex genetic influences contributing to the pathogenic processes in various brain disorders, prematurely raised expections regarding the identification of genes linked to familial forms of unipolar depression, manic-depressive illness, and schizophrenia have led to a great deal of disappointment. There is now a large body of evidence that genetic susceptibility exerts a considerable impact on the aetiology of affective disorders and heritability is estimated be up to 80 %. Although depression and bipolar disorder may share factors which determine depressive symptomatology with an associated high risk of suicide, genetic heterogeneity and a substantial but varying environmental component complicates identification of predisposing genes. Moreover, as in other genetically complex disorders, a susceptibility gene alone is neither necessary nor sufficient to cause the disease. While only few structural changes in the brain are directly related to mental illness, the failure to adapt correctly to external challenges appears to be highly relevant to the pathogenesis of depression. The genetic component in its aetiology is therefore probably more related to dysregulation of gene expression with subsequent alterations in synaptic plasticity and adaptation, than to the generation of gene products with structural changes.
Paralleling the elucidation of gene-environment interaction, it is being realized that gene transfer strategies may eventually be applicable to genetic factors associated with complex non-mendelian disorders (Lesch, 1999) . Moreover, the long-standing dogma that neurons are highly vulnerable and their capacity for regeneration, reproducibility, and plasticity is limited, is presently fading (Davies et al., 1997) . The outcome of conventional therapeutic efforts as well as the outlook for a causal treatment in psychiatric disorders characterized by an early onset and a chronic progressive course of illness with their devastating impact on individual lifes, have generally proven less than satisfactory. While targeting gene regulation or gene transfer approaches are quite appealing, no current technique meets the rigorous requirements obligatory for human trials, and considerable damage to neuronal function may have occurred before the disorder can be diagnosed and treatment established. Nevertheless, while the concept of therapeutic modification of gene expression in severe affective disorders is still in its theoretical infancy, the technical prerequisites are being developed at an incredible pace, thus raising modest hopes for a beneficial application of these treatment strategies in some forms of chronic and treatment-resistant conditions.
